Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

24. Juni 2025 15:59 ET | Quelle: Abvance Therapeutics

Abvance Therapeutics Secures Strategic Seed Financing & Leadership Expansion at ADA Scientific Sessions

Abvance closes seed round led by Zubi Capital to advance glucagon-based therapies aimed at preventing hypoglycemia in people with diabetes.
21. Juni 2025 13:50 ET | Quelle: Abvance Therapeutics

Abvance Therapeutics Announces Presentation of Human Clinical Data at the 85th Scientific Sessions of the American Diabetes Association

Abvance presents first-in-human data on insulin-glucagon co-dosing in T1D, demonstrating a novel approach to help prevent hypoglycemia
10. September 2024 09:00 ET | Quelle: Abvance Therapeutics

Abvance Therapeutics Announces $3.9M Program Related Investment from the Helmsley Charitable Trust to Support Development of Its Novel Insulin and Glucagon Combined Formulation

Abvance is developing ABV100, a proprietary, clinically validated combination of insulin and glucagon with a goal of improving glycemic control while reducing hypoglycemia for people with diabetes who...